Document Detail

Effect of the Honan intraocular pressure reducer to prevent vitreous reflux after intravitreal bevacizumab injection.
MedLine Citation:
PMID:  22562298     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To evaluate the effect of the Honan intraocular pressure reducer (HIPR) on vitreous reflux during intravitreal (IVT) injection.
METHODS: Prospective, comparative, controlled, investigator-blinded, randomized clinical study. Sixty eyes of 60 patients who underwent IVT injection were allocated into 2 groups with or without using the HIPR. Vitreous reflux was estimated by measuring largest diameter of the conjunctival bleb formed after IVT injection. Preoperative intraocular pressure (IOP) before and after application of the HIPR and IOP immediately postoperatively and 3 and 10 minutes postoperatively were evaluated.
RESULTS: The mean amount of vitreous reflux was significantly less with the HIPR than without the HIPR (1.46±1.04 mm vs 2.61±1.37 mm; p<0.001). The preoperative IOP was significantly lower with the HIPR than without the HIPR (11.62±4.04 mmHg vs 16.26±3.86 mmHg; p=0.026). The 3-minute postoperative IOP was 31.34±3.16 mmHg with the HIPR and 32.61±5.62 mmHg without the HIPR (no statistical significance; p=0.345).
CONCLUSIONS: The HIPR prevents vitreous reflux after IVT through a reduction in the preoperative IOP. However, the HIPR appears not to affect the postoperative course of transient IOP elevation.
Seung Woo Hong; Donghyun Jee
Related Documents :
6635378 - Cardiac output and regional oxygen transport in the acutely hypoxic conscious sheep.
22459928 - Respiratory variations of r-wave amplitude in lead ii are correlated with stroke volume...
3188788 - Pre- and postoperative respiratory muscle strength in primary hyperparathyroidism.
15087288 - Early mitral deceleration and left atrial stiffness.
989608 - Effect of distension on release of surfactant in excised dogs' lungs.
9176778 - Two types of oscillopsia in a patient with idiopathic vestibulopathy.
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  European journal of ophthalmology     Volume:  22     ISSN:  1724-6016     ISO Abbreviation:  Eur J Ophthalmol     Publication Date:    2012 Jul-Aug
Date Detail:
Created Date:  2012-07-13     Completed Date:  2012-10-04     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  9110772     Medline TA:  Eur J Ophthalmol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  615-9     Citation Subset:  IM    
Department of Ophthalmology and Visual Science, Bucheon St. Mary's Hospital, Seoul, Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / administration & dosage*
Antibodies, Monoclonal, Humanized / administration & dosage*
Balloon Occlusion / instrumentation*
Double-Blind Method
Eye Diseases / etiology,  prevention & control*
Intraocular Pressure / physiology*
Intravitreal Injections*
Middle Aged
Prospective Studies
Retinal Diseases / drug therapy
Tonometry, Ocular
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Vitreous Body*
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Surgical intervention in central toxic keratopathy.
Next Document:  Retinal nerve fiber layer thickness variability in Leber hereditary optic neuropathy carriers.